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Abstract
Background: The vascular contributions to neurodegeneration and neuroinflammation may be assessed by
magnetic resonance imaging (MRI) and ultrasonography (US). This review summarises the methodology for these
widely available, safe and relatively low cost tools and analyses recent work highlighting their potential utility as
biomarkers for differentiating subtypes of cognitive impairment and dementia, tracking disease progression and
evaluating response to treatment in various neurocognitive disorders.
Methods: At the 9th International Congress on Vascular Dementia (Ljubljana, Slovenia, October 2015) a writing group
of experts was formed to review the evidence on the utility of US and arterial spin labelling (ASL) as neurophysiological
markers of normal ageing, vascular cognitive impairment (VCI) and Alzheimer’s disease (AD). Original articles, systematic
literature reviews, guidelines and expert opinions published until September 2016 were critically analysed to summarise
existing evidence, indicate gaps in current knowledge and, when appropriate, suggest standards of use for the most
widely used US and ASL applications.
Results: Cerebral hypoperfusion has been linked to cognitive decline either as a risk or an aggravating factor.
Hypoperfusion as a consequence of microangiopathy, macroangiopathy or cardiac dysfunction can promote
or accelerate neurodegeneration, blood-brain barrier disruption and neuroinflammation. US can evaluate the
cerebrovascular tree for pathological structure and functional changes contributing to cerebral hypoperfusion.
Microvascular pathology and hypoperfusion at the level of capillaries and small arterioles can also be assessed
by ASL, an MRI signal. Despite increasing evidence supporting the utility of these methods in detection of
microvascular pathology, cerebral hypoperfusion, neurovascular unit dysfunction and, most importantly, disease
progression, incomplete standardisation and missing validated cut-off values limit their use in daily routine.
Conclusions: US and ASL are promising tools with excellent temporal resolution, which will have a significant impact
on our understanding of the vascular contributions to VCI and AD and may also be relevant for assessing future
prevention and therapeutic strategies for these conditions. Our work provides recommendations regarding the use of
non-invasive imaging techniques to investigate the functional consequences of vascular burden in dementia.
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Background
With the growing burden of dementia, there is an
increasing interest in identifying clinical tools that would
result in early recognition of individuals at risk, differen-
tiate between types of dementia, and eventually lead to
effective prevention or treatment strategies. There is
increasing evidence linking cerebral hypoperfusion and
neurodegeneration, specifically in Alzheimer’s disease
(AD) and vascular dementia (VaD) [1, 2]. Indeed, in the
Rotterdam study [3], cerebral hypoperfusion was demon-
strated to be either a risk or an aggravating factor in
dementia. We also know that chronic hypoperfusion is
not only an epiphenomenon of brain tissue loss but
actively promotes, initiates or accelerates neurodegener-
ation through multiple mechanisms, including induction
of oxidative stress, amyloid beta (Aβ) accumulation and
aggregation, tau hyperphosphorylation, synaptic dys-
function, neuronal loss, white matter hyperintensities
(WMH), and neuroinflammation [4, 5]. Vascular ageing
with consequent chronic hypoperfusion may contribute
to blood-brain barrier disruption which, according to
emerging in vivo imaging evidence, occurs relatively
early in life in selected areas, such as hippocampus,
making affected individuals prone to development of
memory disorders [6, 7]. A better understanding of the
mechanisms underlying cerebral hypoperfusion could
lead to effective therapeutic strategies targeted at treat-
ing both AD and VaD [8].
Changes in cerebral microcirculation are observed in
normal ageing as well as in the broad spectrum of vas-
cular cognitive impairment (VCI), ranging from vascular
mild cognitive impairment (MCI) to VaD. Besides alter-
ations at the level of cerebral microcirculation, which
are thought to play a major role in the development of
VCI, there is evidence that large vessel pathology, in
particular atherosclerosis, and modifiable vascular risk
factors such as hypertension, may also contribute to
cognitive decline [9–11]. Ultrasonography (US) may be
used to identify modifiable risk factors known to pro-
mote dementia. For instance, atherosclerotic burden, as
defined by carotid ultrasound, was associated with worse
cognitive performance and subsequent cognitive decline
in the Tromsø and other studies [12, 13]. Cerebral
microembolism is also recognised as a mechanism
contributing to VCI. The negative impact of the number
of microscopic emboli on cognition following surgical
procedures, measured using transcranial Doppler ultra-
sound (TCD), has been well established in cardiac and
vascular surgery procedures [14–16].
Recent studies have started to use TCD to examine the
relationship between cerebral small vessel function and
MRI changes attributed to small vessel disease in motor
and cognitive disorders [17–22]. While TCD cannot
match the spatial resolution of functional MRI or positron
emission tomography (PET), it is superior to the other
functional neuroimaging methods due to an excellent
temporal resolution (5 ms) and it is easy to apply and ro-
bust against movement artifacts [23]. A few studies have
shown a link between carotid disease and impaired cere-
brovascular hemodynamics as measured by TCD [24, 25].
Arterial spin labelling (ASL), an MRI technique used to
measure tissue perfusion in capillaries and small arterioles,
can also be used to investigate the role of microvascular
pathology and hypoperfusion in neurodegenerative disor-
ders. ASL measures have shown hypoperfusion mainly in
bilateral parietal areas and precuneus areas in MCI and
mild AD patients. These same areas overlap with the
patterns of hypometabolism on 18F-2-fluoro-2-deoxy-D-
glucose (FDG)-PET in more advanced disease, hence
supporting a role for perfusion monitoring with ASL as a
tool to identify individuals at risk in the pre-clinical state
[26, 27]. Recent work demonstrating the importance of
the glymphatic system for the clearance of Aβ from the
brain via the perivascular space surrounding cerebral
blood vessels [28] provides additional support for altered
microcirculation and functional accumulation of patho-
genic macromolecules (Aβ) as an underlying mechanism
contributing to neurodegeneration.
Methods
At the 9th International Congress on Vascular Dementia
(Ljubljana, Slovenia, October 2015) a writing group of
experts was formed to review the evidence on the utility
of US and ASL as neurophysiological markers of normal
ageing, VCI and AD. The writing group conducted a
comprehensive search in Medline, PubMed and Embase
databases according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
guidelines 2009 [29]. The keywords vascular cognitive
impairment, vascular dementia, Alzheimer disease, cog-
nition, cerebral small vessel disease, ultrasonography,
transcranial Doppler sonography, cerebral autoregulation,
vasoreactivity, neurovascular coupling, microembolism, ca-
rotid ultrasound, intima media thickness, carotid artery
stiffness and arterial spin labelling were used as appropriate
in each database. As an example, in PubMed, the following
search string was applied: ((Ultrasonography, Doppler,
Transcranial[MeSH Terms] OR TCD OR Ultrasonography,
Doppler, Duplex[MeSH Terms] OR “Transcranial Color-
Coded Duplex Sonography” OR “Microembolic signals”
OR “Arterial Spin Labelling” OR “Functional Transcranial
Doppler” OR Hemodynamics[MeSH Terms] OR Carotid
Intima-Media Thickness[MeSH Terms]) AND (Dementia,
Vascular[MeSH Terms] OR Alzheimer Disease[MeSH
Terms] OR “Vascular Cognitive Impairment” OR “Mild
Cognitive Impairment” OR Cognition[MeSH Terms] OR
Cerebral Small Vessel Diseases[MeSH Terms] OR Neuro-
vascular Coupling[MeSH Terms])) AND “English”[Filter]
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AND “humans”[Filter]. After removing the duplicates, ori-
ginal articles, systematic literature reviews, guidelines and
expert opinions in English published until September 2016,
if considered relevant, were critically analysed to summar-
ise existing evidence, indicate gaps in current knowledge,
and, when appropriate, suggest standards of use for the
most widely used US and ASL applications. A PRISMA
flowchart presenting databases search results and final se-
lection of articles is presented in Fig. 1. All members of the
writing group had the opportunity to comment on the
recommendations and approved the final version of this
document. This review is a summary of the current state
of our knowledge on this topic.
Results
Transcranial Doppler (TCD) and transcranial color-coded
duplex sonography (TCCS)
In the 1980s, the introduction of TCD to measure cere-
bral blood flow velocity (BFV) [30] provided a powerful
tool for non-invasive assessment of intracranial vessels.
TCD, which can provide continuous beat-to-beat meas-
urement of the BFV in the basal cerebral arteries, has
become the most commonly utilised tool to study cere-
brovascular haemodynamics in humans [31]. TCD can
be used to non-invasively and repeatedly assess cerebral
vascular responses to various physiological challenges,
such as motor or cognitive activation, or changes in
blood pressure and end-tidal CO2 regulated at the level
of arterioles or resistance vessels of the brain [32–38].
Since the mechanisms underlying each of these vascular
responses are likely different, they have been traditionally
distinguished by different labels. Changes in BFV in re-
sponse to sudden changes in blood pressure are referred
to as dynamic cerebral autoregulation (CA) [32, 33], those
due to changes in end-tidal CO2 (ETCO2) are referred to
as cerebral vasoreactivity (VR) [34, 35], and those due
to motor, visual or cognitive tasks are referred to as
neurovascular coupling (NVC) or functional hyper-
aemia [37, 38]. Neurovascular units maintain homeo-
stasis during periods of increased metabolic demand by
coupling neural activity with cerebral blood flow (CBF).
This functional hyperaemia may have slower onset or
lower amplitudes if uncoupling occurs due to structural or
functional damage of different elements of neurovascular
units (neurotransmitters, pericytes, glia cells, vascular
smooth muscle cells, endothelial cells). In addition to
these three functional measures, the resting cerebral BFV
waveform can also be used to calculate a pulsatility index
(PI = [systolic BFV–diastolic BFV]/mean BFV), which is a
measure of cerebrovascular compliance [39]. Therefore,
the health of the cerebrovascular tree can easily be
assessed using a neurovascular stress test battery that
includes NVC, VR, and dynamic CA, as well as PI.
Main findings
In a recent review by Keage et al. [40], 34 articles were se-
lected for review, of which 29 assessed TCD measures
during rest, 13 during hyper/hypocapnia, and 4 employed
cognitive functional TCD (fTCD) techniques (some arti-
cles presented multiple assessments). The vast majority of
articles assessed differences between demented and non-
demented groups rather than age-related changes (over
50 years).
A number of TCD metrics were employed to assess
CBF at rest. These included mean blood flow velocity
(MBFV), systolic velocity, diastolic velocity, PI and other
resistance measures, and flow asymmetry index (i.e. the
difference between right and left measures at rest); the
majority of studies assessed the middle (MCA) or pos-
terior cerebral arteries (PCA). Other vessels investigated
included the anterior cerebral artery (ACA) and the
basilar artery. Most papers assessed differences between
individuals with and without dementia or dementia pro-
gression; however, some age associations in late life were
reported. These studies showed that the PI increased
with age [41, 42], while mean, diastolic and systolic flow
velocities decreased with age in AD [43] and in the
general population [41]. Most studies reported no sig-
nificant differences in resting MBFV between demented
and control groups [44–52], while others showed lower
MBFV in demented groups, including AD [53–59], VaD
Fig. 1 Flow diagram of the inclusion/exclusion process of the
relevant literature with number of articles at each step
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or multi-infarct dementia [54, 56, 58, 60], regardless of
subtype [61]. The majority of studies reported similar
MBFV in AD and VaD groups [42, 48, 55, 56, 58, 60, 62],
with the exception of one study, where Ries et al. [63]
reported that the multi-infarct dementia group displayed
lower MBFV and diastolic flow velocities compared to
both control and AD groups. Caamaño et al. [58]
reported that individuals with AD and multi-infarct
dementia displayed reduced systolic and diastolic (as
well as mean) flow velocities compared to healthy con-
trols. The two articles which examined an MCI group
assessed MBFV and reported no differences between
the MCI and control groups [53, 64], unless restricting
to amnestic MCI [53]. One study reported that MBFVs
were more asymmetric in an AD group as compared to
healthy controls [57]. In non-demented controls, lower
MBFVs were associated with subsequent cognitive de-
cline and smaller hippocampal and amygdala volumes
[3]. PI was the most commonly employed measure of
vessel resistance and was found to be increased in AD
[47, 53–55, 60, 64] and VaD or multi-infarct dementia
patients [49, 56, 60] as compared to healthy controls,
although this was not the case in two papers [48, 52]. A
number of reports also showed that PI was higher in
individuals with VaD or multi-infarct dementia as
compared to those with AD [42, 48, 52, 58]. However,
in three reports [49, 56, 60], PI was not significantly
different between dementia subtypes. One report
comparing amnesic MCI and controls did not find a
significant difference in PI [47]. Employing a different
calculation of resistance (cerebrovascular resistance
index = (mean blood pressure/cerebral MBFV)), van
Beek et al. [44] also reported higher cerebrovascular
resistance in an AD group.
Methodological issues
Two types of TCD equipment may be used, namely a
non-duplex (non-imaging) or a duplex (imaging) device.
In non-duplex devices, the arteries are identified ‘blindly’
based on the audible Doppler shift and the spectral dis-
play. Specific vessel identification is based on standard
criteria, which include location of the acoustic window,
orientation of the probe, depth of sample volume, direc-
tion of blood flow, and relationship with basal veins
(deep middle cerebral vein for MCA and basal vein of
Rosenthal for PCA), as well as on response to various
manoeuvres such as the common carotid artery com-
pression, which is not currently frequently used, and eye
opening and closing [65].
TCCS imaging combines pulsed wave Doppler US
with a B-mode cross-sectional view of the area of inso-
nation, which allows identification of the arteries in rela-
tion to various anatomic landmarks. The color-coded
Doppler also depicts the direction of the flow in relation
to the probe while recording BFVs. In TCD, the angle of
insonation is assumed to be less than 30° (as close to
zero as possible) to minimise the Doppler shift measure-
ment error. However, in TCCS, the angle of insonation
can be measured and used to correct the flow velocity
measurement. While TCCS significantly increases the
reliability of TCD with better insonation angle correc-
tion [66], the number of studies utilising this method
remains limited and most of the available data are still
based on TCD.
Functional transcranial Doppler (fTCD)
NVC (i.e. blood flow responses to neuronal activation)
can be impaired as a result of neuronal or vascular path-
ology. fTCD is used to assess neurovascular function by
measuring regional changes in cerebral BFV in response
to visual, motor or cognitive challenges. fTCD is a well
validated tool to assess NVC as well as hemispheric lan-
guage lateralisation [67–69].
Main findings
A number of studies have used fTCD to show impaired
neurovascular function long before the appearance of
MRI surrogate measures of small vessel disease or clin-
ical stroke symptoms in patients at a high risk of cere-
brovascular injury; Fabry’s disease is one such example.
In these patients, NVC in the PCA territory is impaired
during a visual challenge, long before they develop clin-
ically overt cerebrovascular disease [70]. Moreover, NVC
is very sensitive to vascular risk factors and has been
shown to be impaired in type 1 diabetic children [71]
and in women with gestational diabetes [72]. Therefore,
fTCD may be a useful pre-clinical screening tool to iden-
tify individuals at a high risk of vascular brain injury
before irreversible damage occurs [73].
fTCD has also been used to assess neurovascular func-
tion in aging. Using a visual stimulation task, it has been
shown that NVC in the PCA is not altered in 10- to 60-
year-old healthy participants [74]. NVC in the ACA
territory, however, may be affected by aging. In a study
involving young and elderly subjects, NVC in the ACA
territory was assessed during an executive cognitive task
and compared to the PCA territory during a visual task.
The results showed that NVC in the ACA territory, but
not in that of PCA, was impaired in the older partici-
pants with generalisation of cerebral activity to compen-
sate for age-related loss of region-specific function [75].
These observations suggest that NVC may be a useful
biomarker of cerebrovascular aging and age-related ex-
ecutive dysfunction.
In addition to the potential use of NVC as a marker of
vascular aging, there is promising data to suggest that
NVC may also be a physiological measure of reserve or
resilience. In a cohort of older community dwelling
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participants, intact NVC was associated with preserved
mobility despite a high burden of cerebral microvascular
disease by MRI [21]. Further, NVC has also been linked
to cognitive function and white matter structural integ-
rity [76]. Therefore, NVC may be a promising thera-
peutic target to enhance network connectivity, mobility
and cognitive function. In fact, there is already promis-
ing data to show that NVC is sensitive to acetylcholin-
esterase inhibitors [77] and flavanols [76].
Methodological issues
The cerebrovascular tree should be fully assessed using
cervical and TCD ultrasound to exclude hemodynamically
significant stenosis in the target territory by fixing moni-
toring probes in an appropriate headframe. Common
standard procedures include simultaneous bilateral PCA
or left PCA plus control right MCA insonation settings
for visual stimuli [70, 78–80] and bilateral MCA for
motor, sensory, cognitive and language tasks [81, 82].
Some studies have also monitored ACA during cognitive
tasks [83]. Proper headframe and stimulus signals re-
corded synchronously with BFV are necessary for accurate
measures. Appropriate duration of resting and stimulation
phases would depend on the chosen stimulus paradigm.
In general, several cycles of rest/activation are averaged to
increase the accuracy of the test.
Different stimulus paradigms have been used depend-
ing on the aim of the study. MCAs have been monitored
during motor, sensory and cognitive tasks [81, 84–87],
ACAs have mainly been recorded during cognitive tasks
[82], while PCAs have been monitored during reading,
flickering light, black/white pattern and checkerboard
stimuli [88].
Collected data may be analysed using a number of
different approaches. Some Doppler systems contain a
software package for this purpose. Alternatively, there
are a number of free or commercial software packages
designed to simplify data analysis (dopOSCCI, AVER-
AGE) [84, 88]. The most commonly analysed parameter
is the (relative) evoked BFV response (EFR), which is
calculated as EFR = [(maximum BFV – resting pre-test
BFV)/resting pre-test BFV] × 100%; it is also commonly
referred to as the overshoot parameter. A more complex
analysis of the dynamic aspects of the visual evoked BFV
response has been developed, described by a control sys-
tem analysis (parameters of time delay, rate time, natural
frequency, attenuation and gain) [78–80, 88].
Limitations
General limitations of all TCD methods are the absence
of an acoustic window, which limits the use in a small
percentage of patients and provides low spatial reso-
lution, i.e. examination is limited to vascular territories
of the circle of Willis. In patients with significant
oscillations in the cardiac cycle (such as atrial fibrilla-
tion) due to oscillations in BFV, the measured values
should be corrected by averaging the activity within a
single heart cycle.
Potential applications
fTCD can be used as a pre-clinical screening tool to
identify individuals at a high risk of vascular brain injury
or to detect early neurovascular dysfunction with ageing
or in high risk patients. Another interesting application
may be to monitor for the therapeutic effects of different
drugs on NVC.
Cerebral vasoreactivity (VR) tests
The response to vasodilatory stimuli, such as CO2 or ac-
etazolamide [89–92], has been traditionally used to
evaluate and quantify cerebral VR, also referred to as
cerebrovascular or vasomotor reactivity. While the exact
mechanisms are unknown, these agents dilate the cere-
bral arterioles and therefore increase CBF [93–95]. Some
have argued that this vasodilatory response may be a
measure of endothelial function in the cerebral vessels
[96]. Cerebral VR is assessed from BFV responses to
rapid changes in ETCO2. The increase in partial pressure
of CO2 induces dilation of cerebral arteries and arterioles,
resulting in a cerebral BFV increase, while a reduction in
partial pressure of CO2 results in vasoconstriction and
BFV decrease. CO2-induced cerebral VR can be measured
either by direct administration of CO2 or with the
breath holding index (BHI); there is extensive literature
reporting both measures in studies of cognition. On the
other hand, only two studies reported using acetazol-
amide and TCD for VR testing in patients with differ-
ent types of dementia [45, 62].
Main findings
One of the first studies to pave the way in testing the link
between VR and cognition was based on the comparison
of VR across controls and patients with dementia
subtypes, and found a marked reduction of vasodilatory
reserve in VaD patients compared to AD patients and
controls [97]. Nevertheless, a more recent study has not
been able to show that VR can differentiate between
dementia subtypes [56].
Further studies in fact showed that cognitive function
is well correlated with BHI in AD patients [98], inde-
pendently of the presence of microvascular ischemic
MRI lesions [55] and with a cut-off value of BHI < 0.69
as a possible predictive marker of MCI conversion to
AD [99]. Other studies also showed that VR assessed by
BHI is significantly reduced in the AD compared to MCI
and healthy controls [100, 101]. These findings are
further supported by a recently reported association
between reduced VR and the APOE ε4+ genotype in
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MCI patients with increased susceptibility to developing
dementia [102]. Therefore, BHI may be a useful bio-
marker to identify MCI subjects at high risk of AD con-
version [101]. Moreover, impaired VR is also associated
with an unfavourable evolution of cognitive function in
AD patients, suggesting that BHI could also be a valu-
able marker for disease progression [98, 103, 104].
Finally, in a cohort of subjects with asymptomatic ca-
rotid stenosis, cerebral VR assessed by BHI has also been
shown to be a strong predictor of cognitive decline
[105]. VR assessment using BHI may be a useful bio-
marker to identify patients with asymptomatic carotid
stenosis at risk for cognitive decline who may benefit
from early surgical revascularisation to prevent further
cognitive decline [24].
Breath holding index (BHI)
Voluntary breath holding leading to hypercapnia can be
used to evaluate vascular reactivity [106]; the procedure
requires a collaborative participant. The BHI has been
validated in patients with internal carotid artery stenosis
or occlusion, compared to other neuroimaging tech-
niques, as a marker of hemodynamic insufficiency and
increased stroke risk [107].
Participants should first be fully trained to perform the
procedure correctly by holding their breath for 30 s
(24 s minimum) after a normal inspiration. They are
connected to a respiratory activity monitor to measure
the exact duration of apnea. Once they are trained,
MBFV at rest is obtained by averaging flow velocities
over a 1-min period of continuous recording at room
air. Participants are instructed to hold their breath. After
breath holding is initiated, MBFV is recorded over a 4-s
interval. ETCO2 at rest and during the first exhalation
after apnea is then evaluated by a capnometer. Outside a
controlled setting, BHI can still be performed as a
screening test without a respiratory activity monitor and
capnometer, but the results are less reliable.
BHI is calculated by dividing the percent of increase in
MBFV occurring during breath holding by the length of
time (in seconds) during which the participant held their
breath after a normal inspiration: BHI = [({MBFV at the
end of breath holding −MBFV at rest}/MBFV at rest) ×
(100/time of breath holding)]. The procedure should be
repeated after a resting period of normal breathing for
3 minutes, and the mean of the two results is considered
for further analysis.
CO2 reactivity test
For this procedure, bilateral MCA BFVs are recorded while
ETCO2 is changed. ETCO2 can be changed by asking sub-
jects to breathe through a standard non-rebreathing mask
with two one-way valves and with an incorporated 2-L res-
ervoir bag; the circuit is connected to a capnometer that
continuously measures ETCO2. Alternatively, the percent
change in MBFV that occurs during breathing an air-CO2
mixture containing 5–8% CO2 is measured through a non-
return valve connected to a mask [108]. Another variation
of this approach is to follow this step with gentle hyperven-
tilation to reduce ETCO2. To calculate VR, MBFV or per-
cent change in MBFV is plotted (y-axis) against ETCO2 (x-
axis); the slope of the linear relationship between MBFV
and ETCO2 is VR [109]. One can also calculate a vasodila-
tory range by measuring the difference between maximum
percent change in MBFV during CO2 inhalation and hyper-
ventilation. A mean vasodilatory range of 88 ± 16% has
been reported in normal individuals [107].
Methodological issues
VR assessment is feasible in most patient populations and
clinical settings. Before proceeding with the VR tests, a
complete extracranial and intracranial examination should
be performed to exclude the presence of a hemodynamic
stenosis that may influence the test results. Since the base-
line values may also affect the vasodilatative or vasocon-
strictive responses, only normocapnic participants should
be included. All participants should abstain from alcohol
and caffeine-containing beverages and smoking for at least
24 h prior to the study due to the possible influence on
vascular reactivity. The examination should be carried out
in a quiet room.
Bilateral simultaneous BFV recordings of MCAs are
obtained using a TCD system with two 2-MHz transduc-
ers fitted on a headband and placed over the temporal
bone window. While the MCAs have been traditionally
assessed using this approach, ACA or PCAs can also be
tested, if needed.
Limitations
The limitations associated with VR measurements are the
same as the general limitations of all TCD methods (See
fTCD section). In addition, the BHI technique is highly
dependent on operator expertise and participant collabor-
ation. To minimise variability, participants should be
trained to perform the procedure correctly, a capnometer
should be used to check the proper execution of the
apnea/breath holding, and the mean value of at least two
tests should be used. There is a false notion that breathing
the air mixture with CO2 could be uncomfortable for pa-
tients. However, since the O2 content of the gas mixture is
the same as room air, with CO2 simply replacing N2, there
is no discomfort to the participant.
Potential applications
While at the present time, BHI is not able to discriminate
among different types of dementia, it may be a useful bio-
marker for identifying individuals at risk of cognitive de-
cline. Given the link between impaired VR and cognitive
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impairment or disease progression, VR may be a promis-
ing therapeutic target for the prevention and treatment of
cognitive disorders.
Cerebral autoregulation
A variety of measures have been used to assess the integ-
rity of CA, but the advantages of TCD have made it the
most commonly utilised tool to study CBF regulation in
humans. Assessment of dynamic CA is based on transient
changes in CBF in response to sudden and rapid changes
in mean arterial pressure (MAP). Sudden changes in MAP
can be induced using a variety of techniques such as the
rapid deflation of bilateral thigh-cuffs [110], hand grip
[111], Valsalva manoeuvre [33, 112, 113], transient hyper-
aemic response test [114, 115], deep breathing, and the
sit-to-stand method [116]. The blood flow response is
then characterised and quantified by a number of derived
variables and reported as specific measures of autoregula-
tion [117]. Alternatively, spontaneous oscillations in arter-
ial blood pressure can be used to calculate the auto- and
cross-spectra of and between arterial blood pressure and
CBF velocity [118–122].
Main findings
CA differs from the already described traditional mea-
sures of VR, namely cerebral VR or vasomotor reactivity.
It is important to remember that, although an intact
endothelium may be necessary for adequate pressure
regulation, traditional VR tests do not detect changes in
cerebrovascular resistance in response to perfusion
changes. Therefore, cerebral VR and CA test different
properties of the cerebrovascular system and should not
be used interchangeably [89, 123, 124].
Impairments in CA occur in a number of conditions
such as stroke, subarachnoid haemorrhage, postpartum
angiopathy, eclampsia, syncope, and traumatic brain in-
jury. Early evidence for impairment of CA in AD came
from animal studies [125]. More recently, data to link
measures of CA to radiographic markers of cerebral hy-
poperfusion and ischemic injury as well as amyloid bur-
den in humans has become available [126–128]. A study
of 48 older individuals showed a strong relationship be-
tween impaired CA and loss of cerebral white matter
structural integrity (WMH and diffusion tensor imaging
metrics) [126]. Similarly, in 14 non-demented elderly
individuals, reduced CA was associated with both in-
creased amyloid deposition and increased WMH volume
[127]. Few studies have examined CA in patients with
AD, but the results remain inconclusive and studies were
limited by their small sample size [128]. Therefore, now
that the link between CA, cerebral hypoperfusion and
amyloid deposition has been established, it is time to ini-
tiate more robust studies of CA in cognitive impairment
and explore the role of CA in dementia subtypes.
Methodological issues
Similar to the VR and NVC test, a complete extracranial
and intracranial examination of the cerebrovascular system
should be performed to exclude any hemodynamically
significant steno-occlusive disease that may influence the
results. Only normocapnic subjects should be considered
and ETCO2 should be monitored during the study to
exclude any significant changes that may influence the
results.
Participants are instrumented with three-lead ECG for
continuous heart rate recording. Beat-to-beat arterial
blood pressure recordings are obtained using a finger
photoplethysmographic cuff. The Finometer transducer
has to be calibrated to height. A 2-MHz TCD transducer
is placed on each temporal acoustic window to measure
the right and left beat-to-beat MCA BFV. The MCAs
are insonated and recorded at a depth of 50–60 mm
using a probe fixation device. All measurements are
obtained continuously for 5 minutes while subjects are
seated upright in a chair. This same approach can be ap-
plied to the ACA, PCA or combination of vessels, and is
not limited to the MCAs.
Frequency-domain transfer function analysis is a valid
method for examining dynamic CA (for a detailed de-
scription please see Meel-van den Abeelen [129] and
Claassen [130]). Using this approach, the relationship
between the spontaneous beat-to-beat fluctuations in
MAP and MBFV is quantified by gain, phase and coher-
ence of the two oscillating waveforms. The phase shift
reflects the temporal difference between transmissions
of oscillation from MAP to MBFV. If the oscillations of
MBFV and MAP are almost synchronous, as in impaired
autoregulation, the phase shift would approach zero,
while higher phase shift represents better autoregulation.
Gain, on the other hand, is the magnitude of transmis-
sion of MAP oscillations to MBFV. Effective autoregula-
tion dampens the transmission of low frequency MAP
oscillations onto MBFV. Therefore, a lower gain in the
low frequency is interpreted as effective autoregulation.
The coherence varies between 0 and 1, and is similar to
a correlation coefficient; it expresses the fraction of
MBFV signal that is linearly associated with MAP in the
frequency domain.
Limitations
The limitations associated with CA measurement are
the same as described for VR and fTCD.
Potential applications
Dynamic CA may be used to monitor responses to
drugs directed at brain amyloid clearance as well as
assessing and monitoring vascular contributions to
neurodegeneration.
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Extracranial ultrasound
Carotid diameter, blood flow velocity, flow and resistance
Main findings
Mean common carotid artery (CCA) diameter and
increased PI are the only two ultrasound parameters that
have been independently associated with WMH score
after adjusting for demographic characteristics and
vascular risk factors [18]. Studies have shown that the
pulsatility of the internal carotid artery (ICA) is higher
in patients with WMH than those without [131–134].
An increased or normal systolic velocity and decreased
ICA diastolic velocity has also been commonly described
in association with WMH [18, 133, 134]. A recent study
showed decreased BFV and blood flow at all stages of
the hemodynamic cycle in patients with WMH com-
pared to the risk factor-matched control group [135].
Aribisala et al. [134] found a correlation between lower
ICA diastolic BFV as well as diastolic blood pressure
and WMH. These findings suggest diastolic hypoperfu-
sion as a possible underlying mechanism of WMH.
Furthermore, Schreiber et al. [136] described reduced
global CBF and prolonged cerebral circulation time in
patients with VaD as well as in AD compared to controls.
Authors suggested that multimodal ultrasound evaluation
could help assess the extent of changes in global cerebral
hemodynamics in patients with dementia but does not
allow for a differentiation between VaD and AD.
Methodological issues
The patient is usually examined in a supine position
with the neck extended and the head inclined by 30o. A
high frequency linear probe (7 MHz or higher) is used
for the standard colour-coded duplex sonography (B
mode, colour and pulse Doppler method). Bilateral
CCA, carotid bulb, ICA and vertebral arteries should be
examined in both transverse and longitudinal planes.
Carotid artery diameter measurements are performed
in the longitudinal plane, strictly perpendicular to the
ultrasound beam, with both proximal and distal walls
clearly visualised. The diameter is usually defined as the
distance between the proximal and distal intimal layer.
Peak-systolic and end-diastolic BFV in all arteries are
measured.
PI can be calculated from the same formula used for
TCD (see TCD section) and the resistivity index can be
calculated using the following formula: RI = peak
systolic velocity – end diastolic velocity/peak systolic
velocity). Cerebral blood flow can be calculated using
the MBFV and diameters of both ICAs and vertebral
arteries (CBF = Σ(MBFV ×Π × [diameter/2]2)).
Limitations
Analysis may be difficult to perform if a patient has a
short contour of the neck. In cases where CCA bifurcation
is positioned high in the neck it may be difficult to visual-
ise the ICA.
Carotid plaque evaluation
Main findings
The relationship between WMH and unstable plaques
suggest that, in addition to atherosclerosis in the cere-
brovascular tree and global hypoperfusion, cerebral em-
bolism may also contribute to cerebral vascular injury,
white matter damage and neuronal loss. Instability of
plaques as determined by ultrasound strain imaging also
correlates with WMH [137]. Carotid intima media thick-
ness (IMT) and plaque burden are also positively corre-
lated with increased WMH lesion burden [138–140].
Therefore, it is possible that changes in microvasculature
similar to carotid pathology and unstable plaques also
contribute to development of WMH.
Methodological issues
Carotid IMT is defined as the maximum distance be-
tween the characteristic echoes from the lumen–intima
and media–adventitia interfaces on the far wall of the
common carotid artery (Mannheim criteria [141]). If
present, carotid plaques (focal structure that encroaches
into the arterial lumen of at least 0.5 mm or 50% of the
surrounding IMT value or demonstrates a thickness >
1.5 mm) should be evaluated in the axial and longitu-
dinal planes.
Limitations
Calcium deposits in the wall of the carotid artery may
make it difficult to evaluate the vessel. A small amount
of soft plaque producing low-level echoes may also go
undetected.
Arterial stiffness evaluation
Main findings
Several studies have shown that aortic stiffness deter-
mined by carotid–femoral pulse wave velocity correlates
with the development, progression and degree of WMH
[131, 142, 143]. According to one theory, increased large
artery stiffness causes small vessel disease by impaired
damping of the arterial waveform and reduced wave re-
flection at the interface of large and small arteries,
resulting in small vessel wall damage due to increased
flow pulsations [144, 145]. A recent study on 549 stroke
and dementia-free middle-aged individuals has shown
that pulse pressure is associated with brain atrophy and
cognitive decline [146]. The study indicates that arterial
stiffening, indexed by simple pulse pressure, may play a
role in early cognitive decline and brain atrophy in mid-
to-late life, particularly among APOE-ε4 carriers [146].
Although carotid–femoral pulse wave velocity is still
considered the ‘gold standard’ for the evaluation of
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arterial stiffness, local carotid stiffness parameters have
also been increasingly used [147]. In addition to being eas-
ily applicable and widely available, local carotid stiffness
parameters show some specific characteristics [148]. For
example, carotid stiffness parameters were found to be
increased in patients with WMH compared to matched
controls [149, 150]. The most powerful carotid stiffness
parameters were pressure strain elasticity modulus and
local pulse wave velocity index beta [149].
Methodological issues
Carotid arterial stiffness measurements are performed in
the same way as IMT; the carotid artery is visualised in
the longitudinal plane, strictly perpendicular to the
ultrasound beam, with both walls clearly visualised.
Arterial stiffness is usually measured automatically from
the changes in the carotid arterial diameter between the
systolic and diastolic phases on CCA segments. Carotid
diameter waveforms are converted to carotid pressure
waveforms using an empirically derived exponential rela-
tionship between pressure and arterial cross-section.
The derived carotid pressure waveform is calibrated to
brachial end diastolic and mean arterial pressure by
iteratively changing the wall rigidity coefficient [151].
This allows the calculation of the arterial stiffness indi-
ces of beta stiffness, pressure-strain elasticity modulus
[147, 152], arterial compliance [152], pulse wave velocity
[153], and augmentation index [152].
Limitations
Carotid stiffness evaluation may be difficult to perform if
a patient has a short neck or in cases where the CCA
lies deep within the tissues and cannot be clearly visua-
lised. A patient’s inability to lie still also makes the
evaluation difficult.
Potential applications
Potential applications of different extracranial ultrasound
methods and parameters are presented in Table 1.
Detection of microembolic signals (MES)
Patients with silent brain infarcts have increased risk of
dementia and a steeper decline in cognitive function
than those without such lesions [154]. One possible
mechanism leading to silent infarcts may be cerebral
microembolisation. The ability of TCD to detect solid
and gaseous asymptomatic microemboli can be used to
identify sources of such emboli in patients at risk (right-
to-left shunts, high risk atherosclerotic plaques, vascular
or cardiac surgeries). Early interventions to prevent
silent microembolisation may be useful in preventing
silent infracts and subsequent cognitive decline.
Main findings
Purandare et al. [155] assessed the relationship between
spontaneous resting MES and dementia and showed that
the presence of MES was significantly associated with
Table 1 Potential applications of extracranial ultrasound in vascular dementia (VaD) and Alzheimer’s disease (AD)
Carotid ultrasound method Finding References
Aortic stiffness (carotid–femoral pulse wave velocity) Increased aortic stiffness in VaD Poels et al., 2012 [142]
Mitchell et al., 2011 [131]
Webb et al., 2012 [132]
Carotid stiffness index Greater CCA stiffness indexes in VaD Morovic et al., 2009 [180]
Jurasic et al., 2009 [181]
Turk et al., 2015 [149]
Carotid pulsatility and resistance index Higher ICA pulsatility in patients with WMH Mitchell et al., 2011 [131]
Webb et al., 2012 [132]
Tanaka et al., 2009 [133]
Aribisala et al., 2014 [134]
Carotid diameter CCA diameter increase in VaD Morovic et al., 2009 [180]
Heliopoulos et al., 2012 [18]
Carotid BFV Higher ICA pulsatility and lower BFV in VaD patients Tanaka et al., 2009 [133]
Aribisala et al., 2014 [134]
Heliopoulos et al., 2012 [18]
Cerebral blood flow Lower CBF in VaD and AD patients compared to controls
Longer CCT in VaD and AD patients compared to controls
Schreiber et al., 2005 [136]
Similar CBF in VaD and AD patients compared to controls Turk et al., 2015 [149]
Plaque instability: Ultrasound strain imaging Increased strain in plaque correlated with WMH Berman et al., 2015 [137]
Intima media thickness and plaque burden Positive correlation between intima media thickness
and plaque burden with WMH lesion burden
Casado-Naranjo et al., 2015 [138]
Heliopoulos et al., 2012 [18]
Kearney-Schwartz et al., 2009 [182]
Shrestha et al., 2009 [140]
BFV blood flow velocity, CBF cerebral blood flow, CCA common carotid artery, ICA internal carotid artery, WMH white matter hyperintensities, CCT cerebral
circulation time
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VaD. In the same large cohort, the group went on to
show a higher incidence of emboli in both VaD (37% of
cases) and AD (40% of cases), as compared to controls
(12% of cases) [156]. Moreover, they showed that the
presence of MES was not only associated with higher
incidence of depression symptoms in patients with
dementia, but that MES were associated with greater
cognitive decline among controls (i.e. non-demented
cases at baseline) [157]. More recently, the group also
showed MES to be associated with faster cognitive and
functional decline in AD and VaD, as well as an in-
creased number of psychiatric symptoms over a 24-
month period [158].
Methodological issues
The influence of US system settings on the detectability
of MES is extremely important and the setup should be
standardised in order to make studies relevant [159].
The methodology for detecting MES was established and
defined by the International Consensus Group on
Microembolus Detection in 1997 [160], which suggested
that all future studies should report microemboli detec-
tion protocols uniformly. Automated detection protocols
can be time saving, but their sensitivity and specificity
still fail to meet requirements for routine clinical use.
Limitations
The time commitments required to perform the examin-
ation and analyse the results can limit the wider applica-
tion of methods in daily practice. Appropriate MES
recognition requires significant expertise to minimise
operator variability and to exclude artifacts which are
not always clearly distinguishable.
Potential applications
Detection and quantification of microemboli in patients at
high risk of developing cognitive decline and dementia.
Improvement of potentially harmful interventional tech-
niques by reduction of microembolic signals [15, 161].
Arterial spin labelling (ASL)
ASL is an MRI technique that allows brain perfusion to
be measured non-invasively at the tissue level. Although
the principle of ASL was introduced in the early 1990s,
it has since significantly benefited from the improved
signal-to-noise ratio of modern high-field MRI systems.
The increasing availability of 3T scanners as well as the
development of improved pulse sequences and multi-
channel receiver array coils has led to a rapidly growing
interest in ASL within the past few years, mainly in
neurological and psychiatric disorders. As a complement
to classic ASL, a dynamic ASL method was also pro-
posed to assess intracranial vascular compliance in brain
aging and dementia [162].
Main findings
Since the widespread use of whole-brain, high signal-to-
noise ratio ASL sequences, several studies have shown
changes in ASL parameters, primarily mean transit time
and time-to-peak of the residue function, in cerebrovas-
cular diseases [163, 164]. Vessel-selective ASL is sensi-
tive to perfusion changes induced by collateral flow in
stroke patients. It has also been applied to cases where
treatment was initiated on the basis of the presence of
collateral flow [165]. A widespread decrease in CBF has
been found in VaD cases, especially in bilateral frontal
and parietal areas but also in individuals with confluent
incidental white matter ischemic changes [166] and
post-stroke patients [167].
In clinically overt AD, ASL studies have consistently
shown a reduction in CBF in a posterior parietal distri-
bution, including the precuneus, posterior cingulate,
angular gyrus, and superior parietal gyrus [168, 169]; for
a recent review see Montagne et al. [170]. The ASL pat-
tern is similar to that of FDG-PET hypometabolism and
both modalities have a similar diagnostic performance
[171, 172]. Moreover, ASL patterns seem to follow the
progression of cognitive decline, suggesting that this
imaging modality may also be a promising biomarker of
disease progression. However, young at-risk cases may
display transient hyperperfusion due to an uncoupling
between CBF and local metabolic needs during differ-
ent phases of the disease. Recently, the capillary het-
erogeneity transition time was proposed as a reliable
marker of the biphasic nature of CBF responses in
preclinical AD [173].
Most importantly, ASL imaging, performed at baseline,
demonstrated decreased perfusion in the posterior cin-
gulate cortex in elderly individuals who later developed
subtle cognitive decline. Interestingly, the ASL pattern
was similar between MCI cases and ‘normal’ controls
who subsequently developed cognitive decline. These
findings suggest that ASL may be a valuable predictive
tool for identifying individuals in the preclinical state
who have reduced CBF and are at a high risk for disease
progression and cognitive decline despite an ‘intact’
cognitive status [174].
Methodological issues
ASL is based on magnetically labelling inflowing arterial
blood protons prior to their entry into the tissue of inter-
est. As such, it can be viewed as a tracer technique with
water acting as the natural endogenous tracer to estimate
tissue perfusion. The label is created by applying radio-
frequency pulses to invert the bulk magnetisation of water
protons in blood. Images are acquired after the labelling
and inflow period using rapid acquisition techniques such
as echo-planar imaging, gradient and spin echo imaging,
or three-dimensional fast spin-echo imaging using a stack-
Malojcic et al. BMC Medicine  (2017) 15:27 Page 10 of 16
of-spirals approach [175]. A pair of images is always ac-
quired, namely a labelled image, in which the blood water
magnetisation is inverted, and a control image, in which
the blood water magnetisation is not inverted. The signal
difference between labelled and non-labelled images is
proportional to the amount of magnetisation inverted and
delivered to the tissue. If all the labelled blood has arrived
at the imaging voxel at the time of image acquisition, the
signal difference will be proportional to CBF. The current
main implementations of ASL are pulsed and pseudo-
continuous labelling (which guarantees higher signal-to-
noise ratio). The use of background suppression and
segmented three-dimensional readout without vascular
crushing gradients is also recommended mainly in cases
with cognitive deficits in order to avoid significant artifacts
[176]. While some of these artifacts may decrease the
diagnostic value of ASL by degrading the images or mim-
icking pathology, others are of clinical utility because they
increase the probability of AD pathology [177].
Limitations
Due to the low perfusion levels and long arterial arrival
times in white matter, the signal-to-noise ratio of the
ASL signal is typically very low. Thus, it is not possible
to obtain reliable estimates of CBF in the deep white
matter unless the acquisition parameters are optimised
[178]. Therefore, ASL imaging is not as sensitive to per-
fusion changes in the deep white matter as in the cortex.
Several studies have shown fair to good concordance
of ASL with measures of perfusion deficit, primarily
time-based parameters such as the mean transit time
and time-to-peak of the residue function [163]. Vessel-
selective ASL is more sensitive in the identification of
perfusion changes induced by collateral flow in stroke
patients. ASL may also be useful in situations where
treatment is initiated on the basis of the presence of
collateral flow patterns [165].
Potential applications
Since MRI is part of routine workup of cognitive decline
in many clinical and research settings, ASL is a cost-
efficient and operator-independent tool for the assess-
ment of early cognitive decline, which simply prolongs
an already existing assessment for a few minutes. ASL
could be useful as a predictive preclinical AD marker
allowing for the identification of healthy controls at risk
for AD dementia. Due to the known coupling between
brain perfusion and metabolism, ASL may be used as a
surrogate marker for FDG-PET. In the future, ASL could
be combined with amyloid and tau PET imaging in the
identification of healthy individuals with an already
active AD process.
Conclusions
Diagnostic tools that can provide real-time functional
assessment of the cerebrovascular tree will have a sig-
nificant impact on our understanding of the vascular
contribution to neurodegeneration at different stages of
cognitive decline. A large body of evidence is now emer-
ging to show the utility of TCD and carotid ultrasound
in providing rapid assessment of cerebrovascular haemo-
dynamics. The biggest advantage of these US techniques
is their excellent time resolution, wide availability and
relatively low cost.
Emerging studies highlight the potential contribution of
VR to early detection of high-risk MCI patients who will
develop VaD or AD and of patients with carotid stenosis at
risk of cognitive decline [99–102]. Similarly, a growing
number of publications have started to examine NVC and
fTCD in vascular ageing and as a measure of physiological
reserve [73–75]. Other emerging studies are beginning to
link impaired CA, increased CCA diameter and PI to MRI
measures of cerebral small vessel disease such as WMH
and white matter microstructural integrity using diffusion
tensor imaging [126, 133–135, 137]. In fact, a recent study
linking impaired CA to amyloid deposition provides the
most promising mechanistic link between vascular disease
and neurodegeneration [127].
However, we have only begun to scratch the very tip
of this iceberg and TCD and US technology as tools to
study vascular contributions to dementia are at their in-
fancy. The technological aspect of US devices has not
changed in recent years, but there is a constant develop-
ment of new analytical tools enabling a better under-
standing of microvascular effects on blood flow in
standardly insonated large arteries [179]. There is a sig-
nificant need for a greater application of these tools
across the spectrum of neurodegenerative disorders. We
need to test these tools in large longitudinal epidemio-
logical studies, smaller mechanistic studies and thera-
peutic clinical trials testing various interventions.
Similar studies are also emerging to show the applica-
tion of ASL in assessing vascular function at the micro-
vascular and capillary level, while providing detailed
spatial resolution in patients with dementia [168–170].
Analogous to US studies, ASL studies suffer from small
numbers and inadequate sample sizes. The immediate
clinical utility of ASL and US also remains quite limited
because most measures lack validated cut-off points to
distinguish between normal and pathological cases.
This review of evidence and suggested standards for
the performance of examinations aims to raise aware-
ness of the promise that these tools hold as preclinical
markers of vascular pathology in neurodegeneration
and their utility in assessing disease progression and/or
response to therapy. Another aim is to encourage more
investigators to apply these tools and measures in their
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studies of neurodegeneration and to thus increase the
pool of such publications. Therefore, we strongly en-
courage the application of US and ASL to evaluate
patients with vascular risk factors who are at risk of
cognitive decline and/or conversion to dementia.
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